

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/090525 A1

(51) International Patent Classification:

<i>A61K 47/69</i> (2017.01)	<i>A61K 39/00</i> (2006.01)
<i>A61K 9/127</i> (2025.01)	<i>A61K 31/7088</i> (2006.01)
<i>A61K 9/51</i> (2006.01)	<i>C07K 14/705</i> (2006.01)
<i>A61P 35/00</i> (2006.01)	<i>C07K 16/28</i> (2006.01)
<i>B82Y 5/00</i> (2011.01)	<i>C12N 15/113</i> (2010.01)
<i>A61K 31/711</i> (2006.01)	<i>C12N 15/62</i> (2006.01)

(21) International Application Number:

PCT/US2024/052438

(22) International Filing Date:

22 October 2024 (22.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/592,197	22 October 2023 (22.10.2023)	US
63/598,347	13 November 2023 (13.11.2023)	US
63/641,887	02 May 2024 (02.05.2024)	US
63/677,895	31 July 2024 (31.07.2024)	US

(71) Applicant: **TESSERA THERAPEUTICS, INC.**
[US/US]; 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US).

(72) Inventors; and

(71) Applicants: **DOUSIS, Athanasios Dimitry** [US/US]; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **ZENG, Chunxi** [CN/US]; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US).

(72) Inventors: **WANG, Zhan**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **ZHANG, Rui**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **GU, Han**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **WANGWEERAWONG, Apiwat**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **TOZZI, Lorenzo**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **LIU, Lei**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **PALCHAUDHURI, Rahul**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **GUPTA, Mohit**; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US). **MONTE,**

Michael; c/o Tessera Therapeutics, Inc., 101 South Street, Suite 300, Somerville, Massachusetts 02143 (US).

(74) Agent: **SNYDER, Seth et al.**; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105-2482 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: LIPID NANOPARTICLES FOR DELIVERY OF THERAPEUTIC PAYLOADS TO T CELLS

(57) Abstract: The disclosure provides conjugates comprising a targeting moiety a lipid nanoparticle (LNP) encapsulating a therapeutic agent (e.g., payload) for delivery to immune cells. The conjugates can be delivered to immune cells *ex vivo* or formulated in a pharmaceutical composition and can be directly administered to a subject in need of (i.e., via *in vivo* administration).



WO 2025/090525 A1